LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Начало・Списък с акции・Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

43.78 1.37

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

42.72

Максимум

44.4

Ключови измерители
By Trading Economics
Приходи	-6.2M -91M
Марж на печалбата	-867.293
Служители	316
EBITDA	4M -90M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+27.13% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	139M 3.4B
Предишно отваряне	42.41
Предишно затваряне	43.78

Настроения в новините

By Acuity

50%

165 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

34.81 / 38.24 Подкрепа & съпротива

Xenon Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

19.12.2025 г., 17:29 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19.12.2025 г., 16:47 ч. UTC

Значими двигатели на пазара

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19.12.2025 г., 16:10 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

19.12.2025 г., 22:33 ч. UTC

Печалби

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19.12.2025 г., 22:19 ч. UTC

Печалби

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19.12.2025 г., 21:48 ч. UTC

Придобивния, сливания и поглъщания

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19.12.2025 г., 21:44 ч. UTC

Печалби

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19.12.2025 г., 21:38 ч. UTC

Печалби

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19.12.2025 г., 21:00 ч. UTC

Пазарно говорене

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19.12.2025 г., 20:23 ч. UTC

Пазарно говорене

Oil Futures End Down Week on Up Note -- Market Talk

19.12.2025 г., 20:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19.12.2025 г., 18:38 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19.12.2025 г., 18:00 ч. UTC

Пазарно говорене

Печалби

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19.12.2025 г., 17:41 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19.12.2025 г., 17:24 ч. UTC

Пазарно говорене

Печалби

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

19.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

19.12.2025 г., 16:29 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19.12.2025 г., 16:20 ч. UTC

Придобивния, сливания и поглъщания

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19.12.2025 г., 16:19 ч. UTC

Придобивния, сливания и поглъщания

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19.12.2025 г., 16:18 ч. UTC

Придобивния, сливания и поглъщания

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19.12.2025 г., 16:16 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

19.12.2025 г., 16:16 ч. UTC

Пазарно говорене

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19.12.2025 г., 16:05 ч. UTC

Придобивния, сливания и поглъщания

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19.12.2025 г., 16:04 ч. UTC

Придобивния, сливания и поглъщания

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19.12.2025 г., 15:37 ч. UTC

Пазарно говорене

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

19.12.2025 г., 15:21 ч. UTC

Пазарно говорене

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

19.12.2025 г., 15:09 ч. UTC

Пазарно говорене

Gold Flat But Set for Weekly Gains -- Market Talk

19.12.2025 г., 15:09 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

19.12.2025 г., 15:09 ч. UTC

Печалби

FedEx Earnings Were Strong. The Stock Is Down. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Xenon Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

27.13% нагоре

12-месечна прогноза

Среден 54.96 USD 27.13%

Висок 65 USD

Нисък 44 USD

Според 15 анализатори от Wall Street, предложили 12-месечна ценова цел за Xenon Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

15 ratings

Купи

Задържане

Продай

Според 15 анализатори, дали борсови рейтинги на Xenon Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

34.81 / 38.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

165 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.